ArticleScientific reports2025
Optimization of supercritical fluid processes for aripiprazole nanoparticle production using GAS-antisolvent technique and Box-Behnken design.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Particle size reduction makes drugs more soluble and bioavailable in the body. Researchers are increasingly interested in supercritical fluid processes for the production of micro- and nanoparticles in pharmaceuticals. In this research, gas anti-solvent (GAS), polyvinyl pyrrolidone polymer (PVP), and dimethyl sulfoxide (DMSO) solvent processes were used for the first time to produce aripiprazole (antipsychotic drug) nanoparticles. This specific combination has not been previously reported for aripiprazole and represents the main novelty of the study. The effects of different operating conditions were evaluated using a Box-Behenken design, which also sought to highlight the optimal combinations of conditions to obtain the smallest particle size. The effects of temperature (308, 318, and 328 K), pressure (10, 13, and 16 MPa), and APZ/PVP ratio (1, 5, and 9 w/w) on particle size were investigated. The optimum values of temperature, pressure, and APZ/PVP ratio were 312 K, 16 MPa, and 1w/w, respectively, which resulted in the minimum particle size. FTIR, FESEM, DLS, XRD, DSC, and dissolution rate tests were used to investigate changes in physical - chemical properties. Good results were obtained by reducing the particle size from 104.6 ± 30.1 μm to 389.6 ± 24.2 nm at optimum condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.